Low-Dose Aspirin and Cancer Prevention in Older Adults

New analysis from the ASPREE study explores who may benefit—or be harmed—by daily aspirin use for cancer prevention.

A secondary analysis of the ASPREE trial suggests that low-dose aspirin may reduce cancer risk in certain older adults but increase it in others, pointing toward a complex, individualized relationship between aspirin, aging, and cancer biology.

Study Details:

The ASPREE (Aspirin in Reducing Events in the Elderly) trial originally enrolled over 19,000 adul…